HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just done ... drastically cut prices to all its prom dresses already, ... 2015. Many of the hottest styles are sold here ... and more. , A spokesman for MissyDress says, “The ... princess prom dresses or sweetheart chiffon prom dresses, you ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 An improving ... sector have benefited the Massage Services industry ... characteristics of industry products, the anticipated 1.0% annualized increase ... has provided consumers with the means to afford additional ... received a massage in a given year has declined ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 DePuy ... a metal-on-metal version of the artificial hip system ... state and federal courts, Bernstein Liebhard LLP reports. ... Bergen County Superior Court on December 2nd, counsel ... begin deposition of plaintiffs on November 19, 2014, ...
(Date:12/20/2014)... 20, 2014 (HealthDay News) -- The holidays can be ... contend with fresh trees, scented candles and other allergy ... the decorations that have been packed away in dank ... allergy and asthma patients," Dr. Rachna Shah, an affiliate ... Medicine, said in Loyola news release. Shah, who ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey ... decade. They’ve treated over 40,000 patients while carrying out ... alternative to the Paramus area. , For 2015, the ... staff of top-notch board certified physicians: Christine Milosis MD, Sandra ... new doctors will work tirelessly to carry out The ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... 2014 Registreer nu via  http://bit.ly/ag8Sypm14de ... 20. Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen ... PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der Aegate ... neue profitablen Unternehmensdienstleistungen, die für Apotheken und ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
Cached News: